Has Rajan Karuvelankulam Subbiah, MD received payments from drug or device companies?

Yes. Drug and device makers reported $916 in general payments to Rajan Karuvelankulam Subbiah, MD across 8 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Rajan Karuvelankulam Subbiah, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Rajan Karuvelankulam Subbiah, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Rajan Karuvelankulam Subbiah, MD

Pulmonary Disease · Rock Hill, NYNPI 1598984601

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 8 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Sanofi at 34.3% of the total. 2025 is the largest year on record at $272, 2.6 times the $104 reported in 2019. That places this record below the midpoint for pulmonary disease clinicians in NY, where the typical reported total is $756.

$916in general payments, 2019–2025

Across 8 payments — averaging $114.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Sanofi$314
Inspire Medical Systems, Inc.$147
Regeneron Healthcare Solutions, Inc.$126
United Therapeutics Corporation$123
Johnson & Johnson$104
Mylan Specialty L.p.$103

What the payments were for

Food & beverage$916100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Sanofi	3	$314
Inspire Medical Systems, Inc.	1	$147
Regeneron Healthcare Solutions, Inc.	1	$126
United Therapeutics Corporation	1	$123
Johnson & Johnson	1	$104
Mylan Specialty L.p.	1	$103

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

DUPIXENT$242
Inspire$147
TYVASO$123
XARELTO$104
Yupelri$103

How this compares

$916 in reported general payments places this provider in the 50th percentile of 1,115 pulmonary disease providers in New York.

See all pulmonary disease providers in New York →

Medicare billing

Part B allowed, 2024

$211,927

Medicare patients

595

Services billed

2,656

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
OfevNintedanib Esylate	23	$320,009
Breztri AerosphereBudesonide/Glycopyr/Formoterol	266	$254,790
Trelegy ElliptaFluticasone/Umeclidin/Vilanter	236	$239,586
Dupixent SyringeDupilumab	24	$105,699
Spiriva RespimatTiotropium Bromide	103	$81,131
Combivent RespimatIpratropium/Albuterol Sulfate	121	$71,699
Breo ElliptaFluticasone/Vilanterol	142	$71,004
Incruse ElliptaUmeclidinium Bromide	116	$61,033
SymbicortBudesonide/Formoterol Fumarate	98	$35,488
Advair HfaFluticasone Propion/Salmeterol	66	$32,464
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr	31	$21,274
Bevespi AerosphereGlycopyrrolate/Formoterol Fum	33	$20,797
Albuterol Sulfate HfaAlbuterol Sulfate	639	$19,029
EliquisApixaban	19	$18,144
Fluticasone-SalmeterolFluticasone Propion/Salmeterol	97	$15,644

Paid to pharmacies, not to this prescriber.

Other pulmonary disease in Rock Hill

Jeffrey WolfGreat Neck$892K
Keith HarrisPort Jefferson Station$832K
Jack MannBayside$736K
Raji AyinlaBronx$673K
Charles PowellNew York$654K
Nashat RabadiBuffalo$613K
Craig ThurmJamaica$604K
Michael MandelLarchmont$589K
Sherif El BayadiSyracuse$571K
Ali El AtatBrooklyn$482K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →